Selected Clinical Trials
Selected Clinical Trials
Breast
Phase: II
NCT04001829
Investigator: Karen C. Daily Weinstein, D.O.
Title: Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Phase: I/II
NCT04333706
Investigator: Karen C. Daily Weinstein, D.O.
Title: A Dose Finding Phase 1 of Sarilumab plus Capecitabine in HER2/neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab plus Capecitabine in Stage I-III Triple Negative Breast Cancer with High-Risk Residual Disease (EMPOWER)
Phase: III
NCT01901094
Investigator: Lisa Renee-Palko Spiguel, M.D.
Title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy
Experimental Therapeutics Group
Phase: II
NCT02465060
Investigator: Thomas J. George, M.D., FACP
Title: Molecular Analysis for Therapy Choice (MATCH)
Phase: II
NCT03207347
Investigator: Thomas J. George, M.D., FACP
Title: Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)
Phase: II
NCT03485209
Investigator: Thomas J. George, M.D., FACP
Title: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors (SGNTV-001)
Phase: I/II
NCT03600883
Investigator: Thomas J. George, M.D., FACP
Title: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C
Cancer Control & Population Sciences
Phase: N/A
NCT03385577
Investigator: Deidre Pereira, Ph.D.
Title: Feasibility, Acceptability, and Efficacy of a Yoga Intervention for Distress in Women with Gynecologic, Gastrointestinal, or Thoracic Cancer
Phase: N/A
NCT04468243
Investigator: Lisa Scarton, Ph.D., B.S.N.
Title: A Nurse-led Intervention in Patients with Newly Diagnosed Cancer and Type 2 Diabetes: A Pilot RCT Feasibility Study
Cutaneous
Phase: III
NCT03573401
Investigator: Abel Torres, M.D., J.D., MBA, FAAD, FACMS
Title: A Randomized, Double Blind, Vehicle-controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT)
Gastrointestinal
Phase: II
NCT03483038
Investigator: Thomas J. George, M.D., FACP
Title: A Phase II, Open-label Evaluating the Safety and Activity of naI-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (UF-STO-PANC-004)
Phase: III
NCT04229004
Investigator: Thomas J. George, M.D., FACP
Title: Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Phase: II
NCT04079712
Investigator: Brian Ramnaraign, M.D.
Title: A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Genitourinary
Phase: III
NCT03561220
Investigator: Nancy Mendenhall, M.D., FASTRO
Title: A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer
Phase: II
NCT03658304
Investigator: Paul Luther Crispen, M.D.
Title: A Single Arm Phase II Trial of the Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract
Phase: III
NCT03793166
Investigator: Jonathan Chatzkel, M.D.
Title: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Gynecological
Phase: II
NCT03673124
Investigator: Merry J. Markham, M.D., FACP, FASCO
Title: A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
Phase: II
NCT04393285
Investigator: Martina Murphy, M.D.
Title: A Phase II Study of Abemaciclib in Combination With Letrozole in Recurrent or Metastatic Endometroid Endometrial Cancer
Head and Neck
Phase: II/III
NCT04128696
Investigator: Frederic J. Kaye, M.D.
Title: A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Malignant Hematology
Phase: III
NCT03016130
Investigator: Zeina Al-Mansour, M.D.
Title: A Phase III, Randomized, Clinical Trial Comparing Two Diets in Patients undergoing Hematopoietic Stem Cell Transplant (HSCT) or Remission Induction Chemotherapy for Acute Leukemia and Myelodysplastic Syndrome
Phase: I
NCT03647800
Investigator: Christopher Cogle, M.D.
Title: Phase 1/1B Open-Label, Dose-Escalation Study of APVO436 in Patients with Relapsed or Refractory AML or High-Grade MDS
Phase: I/II
NCT03013998
Investigator: Christopher Cogle, M.D.
Title: A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Neurologic
Phase: Early Phase I
NCT04187872
Investigator: Maryam Rahman, M.D.
Title: Recurrent Brain Metastasis Immune Effects and Response to Laser Interstitial Thermotherapy (LITT) and Pembrolizumab in Combination (TORCH)
Phase: II
NCT03405792
Investigator: David Tran, M.D., Ph.D.
Title: Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy Adjuvant Temozolomide Plus Optune Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma (2-THE-TOP)
Pediatric
Phase: I
NCT03396575
Investigator: Sridharan Gururangan, FRCP
Title: BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy During Recovery from Focal Radiotherapy Alone or Focal Radiotherapy and Dose-intensified Temozolomide (Phase I)
Phase: II
NCT03155620
Investigator: William B. Slayton, M.D.
Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Phase: I
NCT03334305
Investigator: Elias Sayour, M.D., Ph.D.
Title: ACTION Trial: Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I).
Sarcoma
Phase: II
NCT03628209
Investigator: Joanne P. Lagmay, M.D.
Title: A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Thoracic
Phase: II
NCT03624907
Investigator: Anamaria R. Yeung, M.D.
Title: Consecutive Vs. Non-Consecutive Stereotactic Body Radiotherapy For Early Stage Non-Small Cell Lung Cancer
Phase: III
NCT03793179
Investigator: Frederic J. Kaye, M.D.
Title: INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Clinical Trial Navigator
The UF Health Cancer Center’s Clinical Trial NaviGATOR mobile app gives patients and clinicians the ability to browse cancer clinical trials at the center by disease site and criteria, and to contact the center to make referrals or get additional information. The NaviGATOR is available on the web and is also available as an app for mobile devices.